Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Beverly Moy, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med. 2020 Jul 01. PMID: 32610007.
    Citations:    
  2. Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clin Cancer Res. 2020 Jun 22. PMID: 32571788.
    Citations:    
  3. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Jun 18. PMID: 32555425.
    Citations:    
  4. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Jun 02. PMID: 32483359.
    Citations:    
  5. McCarthy AM, Kumar NP, He W, Regan S, Welch M, Moy B, Iafrate AJ, Chan AT, Bardia A, Armstrong K. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer. 2020 Apr 23; 20(1):347. PMID: 32326897.
    Citations:    
  6. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827. PMID: 32145796.
    Citations:    
  7. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15; 26(12):2838-2848. PMID: 32046998.
    Citations:    
  8. Freund KM, Haas JS, Lemon SC, Burns White K, Casanova N, Dominici LS, Erban JK, Freedman RA, James TA, Ko NY, LeClair AM, Moy B, Parsons SK, Battaglia TA. Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. Cancer. 2019 12 15; 125(24):4532-4540. PMID: 31449680.
    Citations:    
  9. Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 Apr; 20(2):145-151.e2. PMID: 31558424.
    Citations:    
  10. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343.
    Citations:    
  11. Sepucha KR, Langford AT, Belkora JK, Chang Y, Moy B, Partridge AH, Lee CN. Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. Med Decis Making. 2019 08; 39(6):642-650. PMID: 31354095.
    Citations:    
  12. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951.
    Citations:    
  13. Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310. PMID: 31004299.
    Citations:    
  14. Irwin KE, Moy B, Fields LE, Callaway CA, Park ER, Wirth L. Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. J Clin Oncol. 2019 06 20; 37(18):1524-1528. PMID: 30986118.
    Citations:    
  15. Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, Chabner BA, Moy B. Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention. Oncologist. 2019 08; 24(8):1048-1055. PMID: 30988039.
    Citations:    
  16. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875. PMID: 30939096.
    Citations:    
  17. Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019 04 01; 30(4):575-581. PMID: 30753274.
    Citations:    
  18. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089. PMID: 30860945.
    Citations:    
  19. Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomaševic Z, Denduluri N, Šeparovic R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Res. 2019 03 11; 21(1):39. PMID: 30867034.
    Citations:    
  20. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. PMID: 30220055.
    Citations:    Fields:    
  21. Winkfield KM, Phillips JK, Joffe S, Halpern MT, Wollins DS, Moy B. Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. J Clin Oncol. 2018 Sep 13; JCO1801132. PMID: 30212297.
    Citations:    Fields:    
  22. Nipp RD, Shui AM, Perez GK, Kirchhoff AC, Peppercorn JM, Moy B, Kuhlthau K, Park ER. Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act. JAMA Oncol. 2018 06 01; 4(6):791-797. PMID: 29596618.
    Citations:    Fields:    
  23. Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res. 2018 04; 16(4):720-727. PMID: 29453314.
    Citations: 3     Fields:    
  24. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomaševic Z, Denduluri N, Šeparovic R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1688-1700. PMID: 29146401.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  25. Van Poznak C, Somerfield MR, Moy B. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary. J Oncol Pract. 2017 12; 13(12):822-824. PMID: 29035617.
    Citations:    Fields:    Translation:Humans
  26. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 2017 Dec 10; 35(35):3978-3986. PMID: 29035643.
    Citations: 3     Fields:    Translation:Humans
  27. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. PMID: 28982747.
    Citations:    Fields:    Translation:Humans
  28. Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM. Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer?. Clin J Oncol Nurs. 2017 Aug 01; 21(4):E99-E105. PMID: 28738044.
    Citations:    Fields:    Translation:Humans
  29. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048. PMID: 28706010.
    Citations: 2     Fields:    Translation:Humans
  30. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 06; 163(3):535-544. PMID: 28324268.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  31. Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Jun 20; 35(18):2062-2081. PMID: 28618241.
    Citations: 7     Fields:    Translation:Humans
  32. Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA. Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). Biomed Opt Express. 2017 Feb 01; 8(2):555-569. PMID: 28270967.
    Citations: 3     
  33. Nipp RD, Moy B. No Conflict, No Interest. JAMA Oncol. 2016 Dec 01; 2(12):1631-1632. PMID: 27560041.
    Citations:    Fields:    Translation:Humans
  34. Jackson JD, Moy B, Evans MK. The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting? Oncologist. 2016 12; 21(12):1411-1413. PMID: 27821795.
    Citations:    Fields:    Translation:Humans
  35. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583.
    Citations: 7     Fields:    Translation:Humans
  36. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. J Natl Cancer Inst. 2016 12; 108(12). PMID: 27389914.
    Citations: 5     Fields:    Translation:Humans
  37. Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, Winkfield K, Percac-Lima S, Chabner B, Moy B. Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. Oncologist. 2016 Apr; 21(4):467-74. PMID: 26975867.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  38. Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78. PMID: 26868124.
    Citations: 6     Fields:    Translation:Humans
  39. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar; 17(3):367-377. PMID: 26874901.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  40. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  41. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92. PMID: 26829011.
    Citations: 2     Fields:    Translation:HumansCells
  42. Melisko ME, Gradishar WJ, Moy B. Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. Am Soc Clin Oncol Educ Book. 2016; 35:e22-9. PMID: 27249727.
    Citations:    Fields:    Translation:Humans
  43. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36. PMID: 26539793.
    Citations: 10     Fields:    Translation:Humans
  44. Evans M, Moy B. Announcing a New Journal Section: Community Outreach. Oncologist. 2016 Jan; 21(1):1. PMID: 26712959.
    Citations: 1     Fields:    Translation:Humans
  45. Powell E, Moy B. Hospitalizations and emergency department use in cancer clinical trial patients. J Clin Oncol. 2015 Oct 10; 33(29_suppl):160. PMID: 28147984.
    Citations:    
  46. Powell E, Moy B. Palliative care consultation for patients enrolled in cancer clinical trials. J Clin Oncol. 2015 Oct 10; 33(29_suppl):139. PMID: 28148062.
    Citations:    
  47. Martin M, Von Minckwitz G, Ejlertsen B, Chia SK, Buyse ME, Mansi J, Gnant M, Holmes FA, Moy B, Iwata H, Wong A, Lalani AS, Bryce R, Bebchuk JD, Delaloge S. Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. J Clin Oncol. 2015 Oct; 33(28_suppl):117. PMID: 28147820.
    Citations:    
  48. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7. PMID: 26371147.
    Citations: 28     Fields:    Translation:Humans
  49. Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30. PMID: 26461004.
    Citations: 5     Fields:    Translation:Humans
  50. Moy B. Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene. Oncologist. 2015 Jun; 20(6):571. PMID: 25986242.
    Citations:    Fields:    Translation:Humans
  51. Nipp RD, Powell E, Chabner B, Moy B. Recognizing the Financial Burden of Cancer Patients in Clinical Trials. Oncologist. 2015 Jun; 20(6):572-5. PMID: 25986245.
    Citations: 5     Fields:    Translation:Humans
  52. Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96. PMID: 25981899.
    Citations: 2     Fields:    Translation:Humans
  53. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56. PMID: 25888246.
    Citations: 5     Fields:    Translation:Humans
  54. Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48. PMID: 25757412.
    Citations: 1     Fields:    Translation:Humans
  55. Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96. PMID: 25752740.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  56. Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF. Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. N Engl J Med. 2015 Jan 08; 372(2):162-70. PMID: 25564900.
    Citations: 1     Fields:    Translation:Humans
  57. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41. PMID: 25564897.
    Citations: 73     Fields:    Translation:HumansCTClinical Trials
  58. Moy B, Jagsi R, Gaynor RB, Ratain MJ. The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book. 2015; 130-7. PMID: 25993151.
    Citations: 3     Fields:    Translation:Humans
  59. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 01; 33(4):340-8. PMID: 25534386.
    Citations: 20     Fields:    Translation:Humans
  60. Polite BN, Griggs JJ, Moy B, Lathan C, duPont NC, Villani G, Wong SL, Halpern MT. American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol. 2014 Dec 20; 32(36):4162-7. PMID: 25403206.
    Citations: 7     Fields:    Translation:Humans
  61. Sulmasy D, Moy B. Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. J Clin Oncol. 2014 Dec 20; 32(36):4039-41. PMID: 25366686.
    Citations: 4     Fields:    Translation:Humans
  62. Powell E, Finkelstein D, Winkfield KM, Percac-Lima S, Chabner BA, Moy B. Alleviating financial burden for cancer patients in clinical trials. J Clin Oncol. 2014 Oct 20; 32(30_suppl):10. PMID: 28141479.
    Citations:    
  63. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Oct 10; 32(29):3307-29. PMID: 25185096.
    Citations: 55     Fields:    Translation:Humans
  64. Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR. Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy. BMC Med Inform Decis Mak. 2014 Aug 20; 14:73. PMID: 25142035.
    Citations: 5     Fields:    Translation:Humans
  65. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50. PMID: 24888816.
    Citations: 30     Fields:    Translation:Humans
  66. Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC. Geriatric oncology for the 21st century: a call for action. J Oncol Pract. 2014 Jul; 10(4):241-3. PMID: 24781365.
    Citations: 4     Fields:    Translation:Humans
  67. Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014 Apr; 19(4):348-9. PMID: 24674874.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  68. Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014 Apr; 19(4):346-7. PMID: 24674873.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  69. Lennes IT, Bloom M, Bohlen N, Moy B. Massachusetts general hospital: improving patient access to the breast oncology clinic. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S25-7. PMID: 24614048.
    Citations:    Fields:    Translation:Humans
  70. Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist. 2014 Feb; 19(2):186-92. PMID: 24449096.
    Citations: 3     Fields:    Translation:Humans
  71. Jagsi R, Sulmasy DP, Moy B. Value of cancer care: ethical considerations for the practicing oncologist. Am Soc Clin Oncol Educ Book. 2014; e146-9. PMID: 24857095.
    Citations:    Fields:    Translation:Humans
  72. Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ. Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomed Opt Express. 2013; 4(12):2911-24. PMID: 24409390.
    Citations: 6     
  73. Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14. PMID: 24197661.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  74. Cheng X, Bhatia A, Specht MC, Smith BL, Moy B, Bardia A. Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. J Clin Oncol. 2013 Sep 10; 31(26_suppl):147. PMID: 28136533.
    Citations:    
  75. Morris PG, Patil S, Chen C, Abbruzzi A, Lehman RJ, Steingart R, Oeffinger KC, Lin NU, Moy B, Come SE, Winer EP, Norton L, Hudis C, Dang CT. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). J Clin Oncol. 2013 Sep 10; 31(26_suppl):167. PMID: 28136572.
    Citations:    
  76. Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145. PMID: 28136532.
    Citations:    
  77. Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol. 2013 Jul 20; 31(21):2678-84. PMID: 23775973.
    Citations: 2     Fields:    Translation:Humans
  78. Kumar P, Moy B. Cancer health disparities and the cost of cancer care: payment model issues. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):633-6. PMID: 23744862.
    Citations: 1     Fields:    Translation:Humans
  79. Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers. 2013 Apr 23; 28(1):17-23. PMID: 23015398.
    Citations: 3     Fields:    Translation:HumansCells
  80. Kumar P, Moy B. The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive? Oncologist. 2013; 18(4):347-9. PMID: 23568002.
    Citations: 1     Fields:    Translation:Humans
  81. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96. PMID: 23234763.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  82. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012 Oct 01; 14(5):R129. PMID: 23025714.
    Citations: 35     Fields:    Translation:Humans
  83. Raj A, Ko N, Battaglia TA, Chabner BA, Moy B. Patient navigation for underserved patients diagnosed with breast cancer. Oncologist. 2012; 17(8):1027-31. PMID: 22752069.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  84. Riley EC, Moy B. Ethical challenges: caring for the underinsured, geographically disadvantaged patient. J Oncol Pract. 2012 Jul; 8(4):215-8. PMID: 23180985.
    Citations:    Fields:    Translation:Humans
  85. Sepucha KR, Belkora JK, Chang Y, Cosenza C, Levin CA, Moy B, Partridge A, Lee CN. Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis Mak. 2012 Jun 08; 12:51. PMID: 22681763.
    Citations: 16     Fields:    Translation:Humans
  86. Moy B, Abernethy AP, Peppercorn JM. Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care. Am Soc Clin Oncol Educ Book. 2012; e4-8. PMID: 24451828.
    Citations: 2     Fields:    
  87. Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, Ollila DW, Sepucha KR. Decision making about surgery for early-stage breast cancer. J Am Coll Surg. 2012 Jan; 214(1):1-10. PMID: 22056355.
    Citations: 19     Fields:    Translation:Humans
  88. Carp SA, Wanyo C, Specht MC, Schapira L, Moy B, Finkelstein DM, Boas D, Isakoff SJ. Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. J Clin Oncol. 2011 Sep 20; 29(27_suppl):60. PMID: 27958134.
    Citations:    
  89. Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24. PMID: 21810680.
    Citations: 41     Fields:    Translation:Humans
  90. Chow L, Xu B, Dirix LY, Moy B, Leip E, Bardy-Bouxin N, Duvillie L, Sarosiek T. Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC). J Clin Oncol. 2011 May 20; 29(15_suppl):614. PMID: 28020644.
    Citations:    
  91. Moy B, Lebrun F, Bellet M, Chow L, Lang I, Xu B, Badwe RA, Hershman DL, Leip E, Bardy-Bouxin N, Duvillie L, Neven P. Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2011 May 20; 29(15_suppl):631. PMID: 28020590.
    Citations:    
  92. Carp SA, Wanyo C, Specht M, Schapira L, Moy B, Finkelstein D, Boas D, Isakoff SJ. Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):10607. PMID: 28022835.
    Citations:    
  93. Goss PE, Barrios CH, Chan A, Chia SK, Delaloge S, Ejlertsen B, Ingle JN, Moy B, Iwata H, Holmes FA, Mansi J, Von Minckwitz G, Han L, Thiele A, Agrapart V, Freyman A, Truscello J, Berkenblit A, Finkelstein D. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS137. PMID: 28022891.
    Citations:    
  94. Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9. PMID: 21372222.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  95. Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg. 2011 Jan; 127(1):18-26. PMID: 21200195.
    Citations: 13     Fields:    Translation:Humans
  96. Moy B, Chabner BA. Patient navigator programs, cancer disparities, and the patient protection and affordable care act. Oncologist. 2011; 16(7):926-9. PMID: 21804070.
    Citations: 10     Fields:    Translation:Humans
  97. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8. PMID: 20479410.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  98. Swan JS, Ying J, Stahl J, Kong CY, Moy B, Roy J, Halpern E. Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. Qual Life Res. 2010 Apr; 19(3):401-12. PMID: 20084464.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  99. Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23. PMID: 19901120.
    Citations: 6     Fields:    Translation:Humans
  100. Ozanne EM, Partridge A, Moy B, Ellis KJ, Sepucha KR. Doctor-patient communication about advance directives in metastatic breast cancer. J Palliat Med. 2009 Jun; 12(6):547-53. PMID: 19508141.
    Citations: 8     Fields:    Translation:Humans
  101. Moy B, Rappold E, Williams L, Kelly T, Nicolodi L, Maltzman JD, Goss PE. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol. 2009 May 20; 27(15_suppl):1043. PMID: 27961107.
    Citations:    
  102. Sepucha KR, Ozanne EM, Partridge AH, Moy B. Is there a role for decision aids in advanced breast cancer? Med Decis Making. 2009 Jul-Aug; 29(4):475-82. PMID: 19329775.
    Citations: 12     Fields:    Translation:Humans
  103. Jacobson BC, Moy B, Colditz GA, Fuchs CS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008 Sep 08; 168(16):1798-804. PMID: 18779468.
    Citations: 12     Fields:    Translation:Humans
  104. Moy B. Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy. Oncologist. 2008 May; 13(5):474-6. PMID: 18515732.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  105. Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD. Institutional academic industry relationships. JAMA. 2007 Oct 17; 298(15):1779-86. PMID: 17940234.
    Citations: 26     Fields:    Translation:Humans
  106. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903. PMID: 17245695.
    Citations: 42     Fields:    Translation:Humans
  107. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007 Jul; 12(7):756-65. PMID: 17673607.
    Citations: 23     Fields:    Translation:Humans
  108. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov. 2007 Jun; 6(6):431-2. PMID: 17633789.
    Citations: 29     Fields:    Translation:Humans
  109. Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10). PMID: 17525937.
    Citations:    
  110. del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol. 2007 Apr; 188(4):1147-50. PMID: 17377060.
    Citations: 33     Fields:    Translation:Humans
  111. Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer. 2007 Feb; 7(6):489-92. PMID: 17386127.
    Citations: 9     Fields:    Translation:Humans
  112. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006 Nov-Dec; 11(10):1047-57. PMID: 17110623.
    Citations: 36     Fields:    Translation:Humans
  113. Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol. 2006 Nov; 17(11):1637-43. PMID: 16936184.
    Citations: 8     Fields:    Translation:Humans
  114. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006 Aug 15; 12(16):4790-3. PMID: 16914563.
    Citations: 19     Fields:    Translation:Humans
  115. Moy B, Park ER, Feibelmann S, Chiang S, Weissman JS. Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. Psychooncology. 2006 Jul; 15(7):623-34. PMID: 16304623.
    Citations: 21     Fields:    Translation:Humans
  116. Moy B, Tu D, Shepherd LE, Pater JL, Whelan TJ, Ingle JN, Goss PE. NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6018. PMID: 27954595.
    Citations:    
  117. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7. PMID: 16293865.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  118. Blanchard K, Colbert JA, Puri D, Weissman J, Moy B, Kopans DB, Kaine EM, Moore RH, Halpern EF, Hughes KS, Tanabe KK, Smith BL, Michaelson JS. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer. 2004 Aug 01; 101(3):495-507. PMID: 15274062.
    Citations: 27     Fields:    Translation:HumansPHPublic Health
  119. Campbell EG, Moy B, Feibelmann S, Weissman JS, Blumenthal D. Institutional academic industry relationship: results of interviews with university leaders. Account Res. 2004 Apr-Jun; 11(2):103-18. PMID: 15675051.
    Citations: 5     Fields:    Translation:Humans
  120. Moy B, Wang JC, Raffel GD, Marcoux JP. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med. 2000 May 08; 160(9):1370-2. PMID: 10809043.
    Citations: 2     Fields:    Translation:Humans
  121. Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VE, Bhuyan BK. P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype. Br J Cancer. 1990 Sep; 62(3):378-84. PMID: 2145026.
    Citations: 2     Fields:    Translation:AnimalsCells
  122. Moy BC, Petzold GL, Badiner GJ, Kelly RC, Aristoff PA, Adams EG, Li LH, Bhuyan BK. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184. Cancer Res. 1990 Apr 15; 50(8):2485-92. PMID: 2317831.
    Citations: 1     Fields:    Translation:AnimalsCells
  123. Moy BC, Prairie MD, Krueger WC, Bhuyan BK. Interaction of CC-1065 and its analogues with mouse DNA and chromatin. Cancer Res. 1989 Apr 15; 49(8):1983-8. PMID: 2702639.
    Citations:    Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Moy's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (333)
Explore
_
Co-Authors (111)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.